At Oxford BioTherapeutics we're developing a range of precision cancer therapies.
These antibody-drug conjugates are a revolutionary new approach,
with the potential to improve the effectiveness of cancer treatment,
while at the same time sparing healthy tissue and reducing side effects.
Key to this approach is precision: precision targeting, precision delivery and precision cancer cell eradication.
At Oxford BioTherapeutics our goal is simple: to transform patients' treatment with 'Precision Cancer Therapy'.
Oxford BioTherapeutics has developed a world-class technology with the power to precisely target the delivery of antibody-based cancer medicines. Teaming this with other proven technologies, we have built the ideal platform to develop novel antibody-drug conjugate therapies for cancer.
We are developing a range of antibody-drug conjugates (ADCs) targeting a wide variety of cancers. In addition to our in-house development programmes, we are collaborating with major pharmaceutical and specialist ADC companies to advance these revolutionary new treatments.
January 15, 2014
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
December 9, 2013
Oxford BioTherapeutics and Menarini Progress Enhanced Antibody for Acute Myeloid Leukemia as First Clinical Development Candidate in $1 Billion Oncology Investment Alliance
June 26, 2013
Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman